Jeffrey explained how BAMS™ Assay Platform simplifies the process for targeted- and discovery-based proteomic applications, by replacing the need for liquidchromatography separation methods in the analysis of complex biological samples by utilizing affinity enrichment (e.g. antibody-based) directed to specific target proteins, prior to MS analysis.
Run time: 17:36 mins
#ChatsWIthChaudhrey Interviews Jeffrey Silva, Director of Product Development, Adeptrix Corporation
Video Credit: Bruker Life Sciences Mass Spectrometry